Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29694450 | 1.00 | KDR (0.40) | KDRKDM4EL3MBTL1FGFR2DRD3 | |
| SCHEMBL3803720 | 0.80 | HPGDS (0.47) | KDRPOLB | |
| SCHEMBL13006325 | 0.80 | CA1 (0.46) | DRD3 | |
| SCHEMBL3798979 | 0.77 | HPGDS (0.44) | KDRPOLB | |
| SCHEMBL29742741 | 0.75 | DGAT1 (0.40) | KDM4ENPC1POLBSLC2A1APOBEC3A | |
| SCHEMBL29694423 | 0.75 | CHRNB2 (0.46) | KDM4E | |
| SCHEMBL24568274 | 0.75 | CHRNB2 (0.46) | KDM4E | |
| SCHEMBL2068387 | 0.74 | KDM4E (0.39) | KDRKDM4E | |
| SCHEMBL24568718 | 0.73 | GSK3A (0.41) | KDRL3MBTL1POLB | |
| SCHEMBL15549532 | 0.73 | LTA4H (0.42) | KDRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116948-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-04-11 | — | — | US | disclosed |
| EP-4267584-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136221-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022136221-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116948-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, TGFBR2 | KDR 42/4885KDM4E 886/4885L3MBTL1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.